BMC Cancer, 2023 Background Urothelial bladder cancer is most frequently diagnosed at the non-muscle-invasive stage (NMIBC). However, recurrences and interventions for intermediate and high-risk NMIBC patients impact the quality of life.
Iliana K. Kerzeli +10 more
doaj +1 more source
Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer? [PDF]
, 2003 Between 1997 and 2000 we investigated in a prospective study the voided urine samples of all consecutive patients undergoing cystoscopy independent from their clinical background (n=705) with the BTA-TRAK(TM) assay (Bard Diagnostics, Redmont, USA ...
Hofmann, Karin +8 more
core +1 more source
Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer [PDF]
, 2018 Although approximately 75% of bladder cancers are non-muscle invasive (NMIBC) at diagnosis, most research tends to focus on invasive disease (e.g., experiences related to radical cystectomy and urinary diversion). There is a lack of studies on quality of
Bogaczyk, Tyler L. +4 more
core +2 more sources
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma [PDF]
, 2013 Background: Proteomic discovery of cancer biomarkers in body fluids is challenging because of their low abundance in a complex background. Altered gene expression in tumours may not reflect protein levels in body fluids.
A Martin +54 more
core +6 more sources
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma. [PDF]
, 2019 Bladder cancer is one of the most common cancers in the United States, but few advancements in treatment options have occurred in the past few decades.
Chang, Eric Y +7 more
core +1 more source
Frontiers in Cell and Developmental Biology, 2021 BackgroundAerobic glycolysis and epidermal–mesenchymal transition (EMT) play key roles in the development of bladder cancer. This study aimed to investigate the function and the underlying mechanism of dihydropyrimidinase like 2 (DPYSL2) in bladder ...
Jun Zou +6 more
doaj +1 more source
The prognostic significance of DAPK1 in bladder cancer. [PDF]
PLoS ONE, 2017 Bladder cancer is one of the leading causes of cancer-related death in men, however, there was only limited effective treatment for invasive bladder cancer.
Jian-Yun Xie +9 more
doaj +1 more source
Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
Heliyon, 2023 The increased activity of the mTOR pathway in bladder cancer has been extensively studied, but no satisfactory mTOR inhibitor has been found in bladder cancer.
Weimin Hu +7 more
doaj +1 more source
Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]
, 2017 RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K +7 more
core +2 more sources
CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
Molecular Cancer, 2021 Background Cisplatin (CDDP) has become a standard-of-care treatment for muscle-invasive bladder cancer (MIBC), while chemoresistance remains a major challenge. Accumulating evidence indicates that circular RNAs (circRNAs) are discrete functional entities.
Hui Zhang +10 more
semanticscholar +1 more source